EMD 6.45% 3.3¢ emyria limited

Ann: June 2023 Quarterly Activities Report and Appendix 4C, page-11

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. fup
    1,126 Posts.
    lightbulb Created with Sketch. 102
    partnering with the big end of town comes with pros and cons. aspen pharma are only paying 400k for milestone payments and the royalty is 10% of NET sales. RX5 is not shooting out the lights, the share price has only gone backwards since the deal was announced. we will only get a big share price boost if there is a US commercial partnership for RX5 on suitable terms, who knows how far away that is when the phase3 trial completion has been pushed back until some date not even the company itself knows
 
watchlist Created with Sketch. Add EMD (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.